Noile-Immune Biotech: Corporate Governance Report 2025/04/01
Noile-Immune Biotech: Extraordinary Report
Noile-Immune Biotech: Matters relating to business plans and growth potential
Noile-Immune Biotech: Confirmation letter
Noile-Immune Biotech: Internal Control Report - 10th Term (2024/01/01 - 2024/12/31)
Noile-Immune Biotech: Financial Report - 10th Term (2024/01/01 - 2024/12/31)
Noile-Immune Biotech: Notice of convocation of the 2025 Annual General Meeting of Shareholders and Shareholders' Meeting Materials
Noile-Immune Biotech: Notice Concerning the Introduction of a Stock Remuneration System with Transfer Restrictions
Noile-Immune Biotech: Summary of financial results for the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
Noile-Immune Biotech: Notice of conclusion of an option agreement with the University of Tokyo regarding polymer compounds for nucleic acid delivery
Noile-Immune Biotech: Notice regarding the selection of loan stocks for our shares
Noile-Immune Biotech: (Correction) Partial Corrections to the “Notice Concerning the Recording of Non-operating Income”
Noile-Immune Biotech: Notice Concerning the Recording of Non-Operating Profit
Noile-Immune Biotech: Notice regarding publication of earnings forecasts
Noile-Immune Biotech: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [Japanese GAAP] (unconsolidated)
Noile-Immune Biotech: Correction Confirmation Form
Noile-Immune Biotech: Revised Semi-Annual Report - Term 10 (2024/01/01 to 2024/12/31)
Noile-Immune Biotech: (Correction) Partial Corrections to the “Notice Concerning Prioritization of Our Drug Discovery Pipeline and Associated Changes in the Use of Funds Raised at the Time of Listing”
Noile-Immune Biotech: Notice regarding a business alliance with Takara Bio Co., Ltd. for the development of NIB103
Noile-Immune Biotech: Semi-Annual Report - Term 10 (2024/01/01 - 2024/12/31)